Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 96194. Отображено 100.
05-01-2012 дата публикации

Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy

Номер: US20120003229A1
Принадлежит: Individual

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Подробнее
27-05-2011 дата публикации

УСТРОЙСТВО ДЛЯ ЖИДКОФАЗНОГО ТЕРМИЧЕСКОГО ОКИСЛЕНИЯ ФТОРОЛЕФИНОВ

Номер: RU0000104870U1

Устройство для проведения жидкофазного термического окисления фторолефинов, включающее стальной реактор с патрубком, электрообогреватель, термопару и приспособление для регулирования температуры, отличающееся тем, что приспособление для регулирования температуры конструктивно выполнено в виде трубчатого змеевика, навитого на верхнюю часть реактора. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 104 870 (13) U1 (51) МПК B01J 10/00 (2006.01) C07D 303/08 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21)(22) Заявка: 2010113819/04, 09.04.2010 (24) Дата начала отсчета срока действия патента: 09.04.2010 (45) Опубликовано: 27.05.2011 1 0 4 8 7 0 R U Формула полезной модели Устройство для проведения жидкофазного термического окисления фторолефинов, включающее стальной реактор с патрубком, электрообогреватель, термопару и приспособление для регулирования температуры, отличающееся тем, что приспособление для регулирования температуры конструктивно выполнено в виде трубчатого змеевика, навитого на верхнюю часть реактора. Ñòðàíèöà: 1 ru CL U 1 U 1 (54) УСТРОЙСТВО ДЛЯ ЖИДКОФАЗНОГО ТЕРМИЧЕСКОГО ОКИСЛЕНИЯ ФТОРОЛЕФИНОВ 1 0 4 8 7 0 Адрес для переписки: 198035, Санкт-Петербург, ул. Гапсальская, 1, ФГП "Ордена Ленина и ордена Трудового Красного Знамени НИИ синтетического каучука имени академика С.В. Лебедева", начальнику ИКЦ П.П. Шпакову (73) Патентообладатель(и): Федеральное государственное унитарное предприятие "Ордена Ленина и ордена Трудового Красного Знамени научноисследовательский институт синтетического каучука имени академика С.В. Лебедева" (RU) R U Приоритет(ы): (22) Дата подачи заявки: 09.04.2010 (72) Автор(ы): Емельянов Геннадий Анатольевич (RU), Родин Виктор Михайлович (RU), Костычева Дарья Михайловна (RU), Кулаченков Сергей Анатольевич (RU) U 1 U 1 1 0 4 8 7 0 1 0 4 8 7 0 R U R U Ñòðàíèöà: 2 RU 5 10 15 20 25 30 35 40 45 50 104 870 U1 Предложение относится к области технологии получения ...

Подробнее
20-03-2014 дата публикации

УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ ТЕРМИЧЕСКИ НЕСТАБИЛЬНЫХ АНГИДРИДОВ ОРГАНИЧЕСКИХ КИСЛОТ

Номер: RU0000138568U1

Устройство для получения термически нестабильных ангидридов органических кислот, характеризующееся тем, что оно содержит реактор термолиза с аксиальной линией подачи органической кислоты из бункера-дозатора и радиальной линией подачи в его верхнюю часть подогретого газа-носителя из нагревателя, вход которого подсоединен к узлу подачи газа-носителя, холодильник с линией подвода хладоагента, сепаратор, контур регулирования температуры нагревателя, состоящий из последовательно соединенных датчика температуры на выходе нагревателя, регулятора расхода теплоносителя и исполнительного клапана на линии подачи теплоносителя в нагреватель, контур регулирования соотношения расходов органической кислоты и газа-носителя в реактор, состоящий из последовательно соединенных датчика температуры на выходе реактора, регулятора расхода газа-носителя в нагреватель и исполнительного клапана на линии подачи газа-носителя в нагреватель, и контур регулирования температуры холодильника, состоящий из последовательно соединенных датчика температуры на выходе холодильника, регулятора расхода хладоагента и исполнительного клапана, при этом выход реактора подключен к холодильнику, линия отвода охлажденных продуктов реакции которого подсоединена к входу сепаратора с линиями отвода газовой фазы продукта, жидкой водной фазы продукта и жидкой неводной фазы целевого продукта. И 1 138568 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ ВУ” 138 568” 44 ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ИЗВЕЩЕНИЯ К ПАТЕНТУ НА ПОЛЕЗНУЮ МОДЕЛЬ ММ9К Досрочное прекращение действия патента из-за неуплаты в установленный срок пошлины за поддержание патента в силе Дата прекращения действия патента: 24.10.2018 Дата внесения записи в Государственный реестр: 01.08.2019 Дата публикации и номер бюллетеня: 01.08.2019 Бюл. №22 Стр.: 1 па 8 9948$ ЕП

Подробнее
05-01-2012 дата публикации

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Номер: US20120004206A1

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Подробнее
12-01-2012 дата публикации

Modulation of anxiety through blockade of anandamide hydrolysis

Номер: US20120010283A1

Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

Подробнее
19-01-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer

Номер: US20120016019A1
Автор: Gee-Hwoon LEE
Принадлежит: Individual

The present invention relates to a compound of the formula I: wherein R is C 2 H 5 or C 2 H 3 , or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating or preventing cancers.

Подробнее
19-01-2012 дата публикации

Method and apparatus for preparing hydroxymethylfurfural

Номер: US20120016141A1
Автор: Hsi-Yen Hsu, Ruey-Fu Shih

In an embodiment of the invention, an apparatus for preparing hydroxymethylfurfural (HMF) is provided. The apparatus includes a reaction area including a first organic layer including sugar and a solvent and a second organic layer including a solvent mixture with azeotropy and extractability, a boiling area including a mixing solution formed by the hydroxymethylfurfural and the solvent mixture, connected with the reaction area, and a distilling area including water and a liquid layer including the solvent mixture, connected to the reaction area. In another embodiment of the invention, a method for preparing hydroxymethylfurfural (HMF) is provided.

Подробнее
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
26-01-2012 дата публикации

Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex

Номер: US20120022116A1
Принадлежит: Corning Inc

Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

Подробнее
26-01-2012 дата публикации

Process for the production of carnitine from beta-lactones

Номер: US20120022288A1
Принадлежит: Lonza AG

The invention relates to a method for the production of L-carnitine, wherein a β-lactone, which is a 4-(halomethyl)oxetane-2-one, is converted into carnitine with trimethylamine (TMA), wherein the β-lactone is not subjected to a basic hydrolysis step before being contacted with the trimethylamine. The invention also relates to a carnitine having a unique impurity profile.

Подробнее
02-02-2012 дата публикации

3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide

Номер: US20120028804A1

The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.

Подробнее
09-02-2012 дата публикации

Hydrogenation process for the preparation of tetrahydrofuran and alkylated derivatives thereof

Номер: US20120035378A1
Принадлежит: EI Du Pont de Nemours and Co

A process is provided for the synthesis of tetrahydrofuran and related compounds by hydrogenation of furan and derivatives, using a sponge nickel catalyst that has been promoted with iron and chromium.

Подробнее
16-02-2012 дата публикации

Substituted acylguanidine derivatives (as amended)

Номер: US20120041036A1
Принадлежит: Astellas Pharma Inc

An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
01-03-2012 дата публикации

Alkylamido Compounds and Uses Thereof

Номер: US20120053244A1
Принадлежит: Individual

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Подробнее
01-03-2012 дата публикации

Methods of Treating Hair Related Conditions

Номер: US20120053245A1
Принадлежит: Individual

Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.

Подробнее
15-03-2012 дата публикации

Methods of making lubiprostone and intermediates thereof

Номер: US20120065409A1
Принадлежит: Apotex Pharmachem Inc

There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I)

Подробнее
22-03-2012 дата публикации

Metallo-beta-lactamase inhibitors

Номер: US20120071457A1
Принадлежит: Individual

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Подробнее
29-03-2012 дата публикации

Method For Improved Bioactivation Of Pharmaceuticals

Номер: US20120077876A1

This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R 1 and R 2 are hydrogen, alkyl, or aryl radicals.

Подробнее
05-04-2012 дата публикации

Method for the synthesis of 5-alkoxymethyl furfural ethers and their use

Номер: US20120083610A1
Принадлежит: Furanix Technologies BV

Method for the manufacture of 5-alkoxymethylfurfural derivatives by reacting a fructose and/or glucose-containing starting material with an alcohol in the presence of a catalytic or sub-stoechiometric amount of heterogeneous acid catalyst. The catalysts may be employed in a continuous flow fixed bed or catalytic distillation reactor. The ethers can be applied as a fuel or fuel additive.

Подробнее
12-04-2012 дата публикации

Compounds for enzyme inhibition

Номер: US20120088762A1
Принадлежит: Onyx Therapeutics Inc

One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.

Подробнее
12-04-2012 дата публикации

Novel 3.2.1-bicyclo-octane compounds

Номер: US20120088922A1

The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of carbonyl and [1,3]dioxolane; R′ is selected from the group consisting of hydrogen and allyl; or R and R′ taken together represent

Подробнее
19-04-2012 дата публикации

Organic Compounds Having Cooling Properties

Номер: US20120095042A1
Автор: Stefan Michael Furrer
Принадлежит: Givaudan SA

Provided are compounds of formula (I) wherein m is 0, 1 or 2; R I is a mono- or bicyclic heterocyclic ring system including one, two or three heteroatoms selected from nitrogen, sulphur and oxygen; R 2 is selected from hydrogen, methyl and ethyl; I) R 3 is hydrogen, methyl, or ethyl; and R 4 and R 5 are independently selected from ethyl and isopropyl; and R 3 , R 4 and R 5 together have at least 6 carbon atoms: or II) any two or all of R 3 , R 4 and R 5 form together with the carbon atom to which they are attached 3-para-menthyl, bornyl, or adamantyl; having cooling properties, their use as cooling agent and compositions including them.

Подробнее
10-05-2012 дата публикации

Compound inhibiting in vivo phosphorus transport and medicine containing the same

Номер: US20120115851A1
Принадлежит: Kyowa Hakko Kirin Co Ltd

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R 5 represents optionally substituted aryl or the like, Z represents —N═CHR 6 R 7 or the like, R 6 and R 7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R 101 and R 102 together form ═O, and R 103 and R 104 represent H, or R 101 and R 104 together from a bond, and R 102 and R 103 together form a bond.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
17-05-2012 дата публикации

Compounds and compositions comprising cdk inhibitors and methods for treating cancer

Номер: US20120121692A1

Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.

Подробнее
17-05-2012 дата публикации

Substituted carbamoylcycloalkyl acetic acid derivatives as nep

Номер: US20120122764A1
Принадлежит: NOVARTIS AG

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.

Подробнее
24-05-2012 дата публикации

Cadherin-11 inhibitors and methods of use thereof

Номер: US20120128693A1
Принадлежит: GEORGETOWN UNIVERSITY

Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.

Подробнее
24-05-2012 дата публикации

Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor

Номер: US20120129870A1
Принадлежит: Janssen Pharmaceutica NV

The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor.

Подробнее
24-05-2012 дата публикации

Process for producing propylene oxide

Номер: US20120130096A1
Принадлежит: Individual

A multiple liquid phase composition and process for preparing propylene oxide including a reaction mixture of: (a) propylene, (b) at least one peroxide compound, (c) at least one catalyst, such as a titanium silicalite-1 (TS-I) catalyst, and (d) and a predetermined amount of a solvent mixture; wherein the solvent mixture comprises at least (i) at least one alcohol, such as methanol, and (ii) at least one non-reactive co-solvent; wherein the solvents are mixed at a predetermined concentration; wherein the non-reactive co-solvent has a different boiling point than propylene oxide; and wherein the resulting propylene oxide product partitions into a high affinity solvent during the reaction. The process of the present invention advantageously produces a waste stream with little or no significant amount of sodium chloride (NaCl).

Подробнее
31-05-2012 дата публикации

Substituted Esters as Cannabinoid-1 Receptor Modulators

Номер: US20120135975A1
Принадлежит: Merck and Co Inc

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

Подробнее
31-05-2012 дата публикации

Process

Номер: US20120136165A1
Принадлежит: SOUTH BANK UNIVERSITY ENTERPRISES LTD

The present invention provides a continuous process for the epoxidation of an olefinic compound with an oxidant, which process comprises reaction of an olefinic compound with an oxidant in the presence of a catalyst in an apparatus that comprises a reactive distillation column, which column comprises (i) a reactive section, which comprises the catalyst (ii) a rectifying section situated above the reactive section and adapted to allow separation of reagents and/or by-products from products (ix) a stripping section situated below the reactive section and adapted to allow separation of product from reagents and/or by-products (x) a vessel situated below the stripping section and adapted to provide a source of heat for the column and in which initial vaporisation of one or more of the reagents can occur, wherein the temperature in the reactive section (i) is a temperature at which the reaction between the olefinic compound and the oxidant takes place and the temperature in the stripping section (iii) is higher than the temperature in the rectifying section (ii).

Подробнее
31-05-2012 дата публикации

process for the production of an olefin oxide

Номер: US20120136166A1
Принадлежит: Shell Oil Co

The invention provides a process for the epoxidation of an olefin, which process comprises reacting a feed comprising an olefin and oxygen in the presence of a catalyst comprising a carrier and silver deposited on the carrier, which carrier comprises at least 85 weight percent α-alumina and has a surface area of at least 1.3 m 2 /g, a median pore diameter of more than 0.8 μm, and a pore size distribution wherein at least 80% of the total pore volume is contained in pores with diameters in the range of from 0.1 to 10 μm and at least 80% of the pore volume contained in the pores with diameters in the range of from 0.1 to 10 μm is contained in pores with diameters in the range of from 0.3 to 10 μm.

Подробнее
07-06-2012 дата публикации

Light-emitting device material and light-emitting device

Номер: US20120138907A1
Принадлежит: TORAY INDUSTRIES INC

Embodiments provide a light emitting device material characterized by containing an anthracene compound represented by the following general formula. where R 19 to R 37 are a hydrogen atom, alkyl group, cycloalkyl group, heterocyclic group or the like; n is 1 or 2; and A is a heteroarylene group or arylene group. Any one of the R 19 to R 27 and any one of the R 28 to R 37 are used for linking with A. The present teachings allow a light emitting device having high luminous efficiency and excellent durability.

Подробнее
07-06-2012 дата публикации

Synthesis of ttx intermediates

Номер: US20120142911A1

The present invention relates to the synthesis of intermediates which are useful in TTX synthesis and to the preparation thereof.

Подробнее
07-06-2012 дата публикации

Method for synthesis of secondary alcohols

Номер: US20120142934A1
Принадлежит: National Tsing Hua University NTHU

A method for synthesis of secondary alcohols is provided for pharmaceutical secondary alcohol by addition of organoboronic acids with aldehydes in presence of the cobalt ion and bidentate ligands as the catalyst. In addition, an enantioselective synthesis method for secondary alcohols is also herein provided in the present invention. The present invention has advantages in using less expensive cobalt ion and commercially available chiral ligands as the catalyst, wide scope of organoboronic acids and aldehydes compatible with this catalytic reaction and achieving excellent yields and/or enantiomeric excess.

Подробнее
14-06-2012 дата публикации

Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Номер: US20120149637A1
Принадлежит: Individual

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Подробнее
14-06-2012 дата публикации

Multifunctional linkers and methods for the use thereof

Номер: US20120149653A1
Принадлежит: RGo Bioscience LLC

In accordance with the present invention, novel multifunctional compounds have been developed which have orthogonal reactive groups thereon, thereby facilitating preparation of compounds having multiple functional properties (e.g., a targeting moiety and a biologically active moiety). Such constructs are useful for a variety of applications, e.g., for the delivery of biologically compatible materials, and release thereof in active form. Therefore, in accordance with the present invention, there are provided multifunctional linkers of defined structure, as well as various derivatives thereof bearing one or more biologically active components thereon. Also provided in accordance with the present invention are methods for the preparation of such constructs, as well as various uses thereof.

Подробнее
14-06-2012 дата публикации

Ruthenium (ii) catalysts for use in stereoselective cyclopropanations

Номер: US20120149906A1
Принадлежит: Vanda Pharmaceuticals Inc

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl 2 (p-cymene)] 2 .

Подробнее
21-06-2012 дата публикации

Phosphorous derivatives as chemokine receptor modulators

Номер: US20120157413A1
Принадлежит: Allergan Inc

The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Подробнее
05-07-2012 дата публикации

Compositions comprising functionalized carbon-based nanostructures and related methods

Номер: US20120171093A1
Принадлежит: Massachusetts Institute of Technology

The present invention generally relates to compositions comprising and methods for forming functionalized carbon-based nanostructures.

Подробнее
05-07-2012 дата публикации

Second-order nonlinear optical compound and nonlinear optical element comprising the same

Номер: US20120172599A1
Принадлежит: Individual

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore. Solution: a chromophore comprising a donor structure D, a π-conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

Подробнее
05-07-2012 дата публикации

Zinc cluster

Номер: US20120172601A1
Принадлежит: Takasago International Corp

Disclosed is a novel zinc cluster compound represented by general formula (1): Zn 4 O (OCOR) 6 (RCOOH) n , wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, and also disclosed are a method for producing the compound and a reaction using the compound.

Подробнее
19-07-2012 дата публикации

N alkylcarbonyl amino lactone compounds and their use

Номер: US20120184608A1
Автор: Edward Tak Wei
Принадлежит: Individual

The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts of irritation, itch, and pain in the skin and in the linings of the oral cavity and upper respiratory tract, for example, in methods of treatment of cough.

Подробнее
19-07-2012 дата публикации

Stilbene Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

Номер: US20120184755A1
Принадлежит: Semiconductor Energy Laboratory Co Ltd

An object is to provide a novel stilbene compound suitable for an organic EL light-emitting material. Provided is a novel stilbene compound represented by a general formula (G1) below. In the formula, Q 1 and Q 2 separately represent an oxygen atom or a sulfur atom; R 1 to R 9 and R 11 to R 17 separately represent any one of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group; α 1 to α 6 separately represent a substituted or unsubstituted phenylene group; Ar 1 and Ar 2 separately represent any one of a substituted or unsubstituted aryl group having 6 to 12 carbon atoms forming a ring, a substituted or unsubstituted dibenzothiophen-2-yl group, and a substituted or unsubstituted dibenzofuran-2-yl group; and j, k, m, n, p, and q separately represent 0 or 1.

Подробнее
26-07-2012 дата публикации

Methods and compositions for heavy metal detoxification

Номер: US20120189721A1
Принадлежит: Metaproteomics Llc

Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.

Подробнее
26-07-2012 дата публикации

Treatment or prophylaxis of proliferative conditions

Номер: US20120190639A1
Принадлежит: UNIVERSITY OF DUNDEE

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

Подробнее
09-08-2012 дата публикации

Compounds for the treatment of hepatitis c

Номер: US20120201783A1
Принадлежит: Bristol Myers Squibb Co

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
09-08-2012 дата публикации

Anti-influenza agents

Номер: US20120202877A1
Принадлежит: Griffith University

The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
23-08-2012 дата публикации

Processes for the production of hydrogenated products

Номер: US20120215014A1
Принадлежит: Bioamber International SARL

A process for making a hydrogenated product includes providing a clarified DAS-containing fermentation broth, distilling the broth to form an overhead that includes water and ammonia, and a liquid bottoms that includes MAS, at least some DAS, and at least about 20 wt % water, cooling and/or evaporating the bottoms, and optionally adding an antisolvent to the bottoms, to attain a temperature and composition sufficient to cause the bottoms to separate into a DAS-containing liquid portion and a MAS-containing solid portion that is substantially free of DAS, separating the solid portion from the liquid portion, recovering the solid portion, hydrogenating the second solid portion in the presence of at least one hydrogenation catalyst to produce the hydrogenated product comprising at least one of THF, GBL or BDO, and recovering the hydrogenated product.

Подробнее
30-08-2012 дата публикации

Guanidine-containing compounds useful as muscarinic receptor antagonists

Номер: US20120219509A1
Принадлежит: Theravance Inc

The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R 1-3 , R 5-7 , a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

Подробнее
30-08-2012 дата публикации

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

Номер: US20120220592A1
Принадлежит: Newron Pharmaceuticals SpA

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

Подробнее
30-08-2012 дата публикации

Furan-Based Curable Compound Derived from Biomass, Solvent-Free Curable Composition, and Method for Preparing Same

Номер: US20120220742A1

The present invention relates to a furan-based curable compound derived from carbohydrate-based biomass, to a solvent-free curable composition, and to a method for preparing thereof, wherein the furan-based curable compound derived from biomass according to the present invention includes two epoxide functional groups bonded to at least one furan-based compound. The present invention may provide an environmentally friendly next-generation curable compound comprising a novel furan-based compound derived from biomass, which may be substituted for curable materials derived from oil resources, as a basic backbone, as well as a composition containing the same. According to the present invention, a curable material, which has a low contraction ratio during curing as compared to conventional radical-type curing materials, may be obtained, and a compound applied to the novel curing material may be prepared with a combination of excellent efficiency and cost-effectiveness.

Подробнее
06-09-2012 дата публикации

Compositions and methods useful for treating diseases

Номер: US20120225851A1
Принадлежит: Eutropics Pharmaceuticals Inc

The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Подробнее
06-09-2012 дата публикации

Microbial production of 3,4-dihydroxybutyrate (3,4-dhba), 2,3- dihydroxybutyrate (2,3-dhba) and 3-hydroxybutyrolactone (3-hbl)

Номер: US20120226055A1
Принадлежит: Massachusetts Institute of Technology

The invention relates to recombinant cells and their use in the production of 3,4-dihydroxybutyrate, 2,3-dihydroxybutyrate and 3-hydroxybutyrolactone.

Подробнее
13-09-2012 дата публикации

Compositions and Methods for Treatment of Eye Disorders

Номер: US20120232019A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Подробнее
27-09-2012 дата публикации

Aryloxyanilide imaging agents

Номер: US20120244073A1
Принадлежит: Individual

The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

Подробнее
18-10-2012 дата публикации

Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use

Номер: US20120264764A1
Принадлежит: Lixte Biotechnology Inc

This invention provides compounds having the structure which may be used for the treatment of tumors.

Подробнее
25-10-2012 дата публикации

Sialochimeric compounds

Номер: US20120269771A1
Принадлежит: Therapicon Srl

The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.

Подробнее
01-11-2012 дата публикации

Processes for making high purity renewable source-based plasticizers and products made therefrom

Номер: US20120277357A1
Принадлежит: Archer Daniels Midland Co

Presently disclosed are high purity unsaturated fatty acid esters with an ester moiety characterized by having from five to seven members in a ring structure, which esters when epoxidized find particular utility as primary plasticizers in flexible polyvinyl halide applications. Also disclosed are processes for making the high purity esters.

Подробнее
01-11-2012 дата публикации

Dendrimer conjugates

Номер: US20120277376A1
Принадлежит: University of Michigan

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.

Подробнее
08-11-2012 дата публикации

Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof

Номер: US20120282180A1
Принадлежит: Siemens Medical Solutions USA Inc

The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention.

Подробнее
15-11-2012 дата публикации

Composite compositions

Номер: US20120289624A1
Принадлежит: Individual

A curable resin composition for composites and electrical laminates including (I) at least one thermoset resin composition; (II) at least one hardener; and (III) at least one reinforcing material; wherein the composite or electrical laminate has a balance of properties including a combination of (a) a Tg of at least about 150° C.; and (b) a water uptake of less than about 2.5 wt %.

Подробнее
22-11-2012 дата публикации

Pyridazine derivatives, processes for their preparation and their use as fungicides

Номер: US20120295876A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

The present invention relates to novel pyridazine derivatives of formula (I) wherein R 1 is methyl or ethyl; R 2 is H or chloro; R 3 is fluoro or chloro; R 4 is fluoro or methoxy; and R 5 is chloro or methoxy or an agrochemically usable salt from thereof, as active ingredients which have microbiodidal activity, in particular fungicidal activity.

Подробнее
29-11-2012 дата публикации

Indanyloxydihydrobenzofuranylacetic acids

Номер: US20120302566A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds defined by formula (I) wherein the variables R 1 , R 2 , R 3 , m, and n are defined as in claim 1 , possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Подробнее
29-11-2012 дата публикации

Process of making alpha-aminooxyketone/alpha-aminooxyaldehyde and alpha-hydroxyketone/alpha-hydroxyaldehyde compounds and a process making reaction products from cyclic alpha, beta-unsaturated ketone substrates and nitroso substrates

Номер: US20120302792A1
Принадлежит: JAPAN SCIENCE AND TECHNOLOGY AGENCY

The present invention is directed to a process of making α-aminooxyketone and α-hydroxyketone compounds. The synthetic pathway generally involves reacting an aldehyde or ketone substrate and a nitroso substrate in the presence of a catalyst of the formula (IV): wherein X a -X c represent independently nitrogen, carbon, oxygen or sulfur and Z represents a 4 to 10-membered ring with or without a substituent and optionally a further step to convert the α-aminooxyketone compound formed to the α-hydroxyketone compound. The present invention results in α-aminooxyketone and α-hydroxyketone compounds with high enantioselectivity and high purity. The present invention is also directed to a catalytic asymmetric O-nitroso Aldol/Michael reaction. The substrates of this reaction are generally cyclic α,β-unsaturated ketone substrate and a nitroso substrate. This methodology generally involves reacting the cyclic α,β-unsaturated ketone substrate and the nitroso substrate in the presence of a proline-based catalyst, to provide a heterocyclic product.

Подробнее
06-12-2012 дата публикации

Sulfonium salt, polymer, chemically amplified resist composition using said polymer, and resist patterning process

Номер: US20120308920A1
Принадлежит: Shin Etsu Chemical Co Ltd

There is disclosed a sulfonium salt shown by the following general formula (1). There can be a sulfonium salt capable of introducing an acid-generating unit generating an acid having an appropriate acid strength and not impairing adhesion with a substrate into a base polymer; a polymer using the said sulfonium salt; a chemically amplified resist composition using the said polymer as a base polymer; and a patterning process using the said chemically amplified resist composition.

Подробнее
06-12-2012 дата публикации

Compounds and methods for treating bacterial infections

Номер: US20120309701A1
Принадлежит: Washington University in St Louis WUSTL

The present invention encompasses compounds and methods for treating urinary tract infections.

Подробнее
13-12-2012 дата публикации

Process for the preparation of an alkylene carbonate and an alkylene glycol

Номер: US20120315198A1
Принадлежит: Shell Oil Co

The invention provides a reaction system for the production of an alkylene carbonate comprising: an epoxidation zone containing an epoxidation catalyst located within an epoxidation reactor; a carboxylation zone containing an bromide-containing carboxylation catalyst located within an alkylene oxide absorber; and one or more purification zones containing a purification absorbent capable of reducing the quantity of bromide-containing impurities in a feed comprising a recycle gas, which purification zones are located upstream from the epoxidation zone; and a process for the production of an alkylene carbonate and an alkylene glycol.

Подробнее
13-12-2012 дата публикации

Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20120316066A1
Принадлежит: Intrexon Corp

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

Подробнее
13-12-2012 дата публикации

Production of liquid fuels (sylvan-liquid-fuels) from 2-methylfuran

Номер: US20120316372A1

The present invention describes a procedure for the production of liquid fuel having a content high in alkanes and low in oxygenated compounds, comprising as a minimum: —a first step of alkylation of 2-methylfuran (commonly denominated Sylvan) with a furan alcohol 2 having the formula: (2), wherein R 1 is H or an aliphatic or aromatic or heteroaromatic moiety, R 2 is H or an aliphatic or aromatic or heteroaromatic moiety, and R 3 is H, hydroxymethyl or an aliphatic or aromatic or heteroaromatic moiety, in the presence of a catalyst, —a second step of hydrogenation and dehydration of the compound obtained in step 1 in the presence of hydrogen, utilising suitable hydrogenation and dehydration catalysts.

Подробнее
20-12-2012 дата публикации

Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof

Номер: US20120322823A1
Принадлежит: PFIZER INC

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Подробнее
20-12-2012 дата публикации

4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Номер: US20120322875A1
Принадлежит: Individual

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

Подробнее
20-12-2012 дата публикации

Process and intermediate compounds useful in the preparation of statins

Номер: US20120323011A1
Принадлежит: Redx Pharna PLC

There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein R a represents an alkyl group, such as a C 1-16 alkyl group, and preferably an isopropyl group; R b represents an aryl group, preferably a 4-fluorophenyl group; R c represents hydrogen, a protecting group or an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO 2 R e group where R e is an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group.

Подробнее
20-12-2012 дата публикации

Method of producing beraprost

Номер: US20120323025A1
Принадлежит: Lung LLC

An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Подробнее
27-12-2012 дата публикации

Inhibitors of hepatitis c virus ns5b polymerase

Номер: US20120328569A1
Принадлежит: Individual

Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Подробнее
27-12-2012 дата публикации

Process for the preparation of dronedarone

Номер: US20120330036A1
Принадлежит: SANOFI SA

The subject of the present disclosure is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide of formula I: and the new intermediates of the preparation process.

Подробнее
27-12-2012 дата публикации

Bis-phosphate compound and asymmetric reaction using the same

Номер: US20120330038A1
Принадлежит: API Corp, Tohoku University NUC

A novel bis-phosphate compound is provided which can be applied to a wide range of reactive substrates and reactions as an asymmetric reaction catalyst and can realize an asymmetric reaction affording a high yield and a high enantiomeric excess. The bis-phosphate compound has a tetraaryl skeleton represented by General Formula (1). In an asymmetric reaction, an amidodiene and an unsaturated aldehyde compound are reacted with each other in the presence of the optically active bis-phosphate compound to give an optically active amidoaldehyde. The invention allows a reaction such as an asymmetric Diels-Alder reaction to proceed efficiently, which has been difficult with conventional mono-phosphate compounds. Thus, the invention enables an industrially feasible method for the production of optically active amidoaldehydes, optically active β-amino acid derivatives, optically active diamine compounds, optically active pyrrolidine derivatives and optically active dihydropyran derivatives which are useful as products such as medicines, agricultural chemicals and chemical products as well as synthesis intermediates for such products.

Подробнее
03-01-2013 дата публикации

Preparation of 2,2-bis (fluoroalkyl) oxirane and preparation of photoacid generator therefrom

Номер: US20130005997A1
Принадлежит: Shin Etsu Chemical Co Ltd

A 2,2-bis(fluoroalkyl)oxirane (A) is prepared by reacting a fluorinated alcohol (1) with a chlorinating, brominating or sulfonylating agent under basic conditions to form an oxirane precursor (2) and subjecting the oxirane precursor to ring closure under basic conditions. R 1 and R 2 are fluoroalkyl groups, R 3 and R 4 are hydrogen or monovalent hydrocarbon groups, X is chlorine, bromine or —OSO 2 R 5 group, and R 5 is alkyl or aryl.

Подробнее
10-01-2013 дата публикации

Monomers, polymers, photoresist compositions and methods of forming photolithographic patterns

Номер: US20130011783A1

Provided are (meth)acrylate monomers containing acetal moieties, polymers containing a unit formed from such a monomer and photoresist compositions containing such a polymer. The monomers, polymers and photoresist compositions are useful in forming photolithographic patterns. Also provided are substrates coated with the photoresist compositions, methods of forming photolithographic patterns and electronic devices. The compositions, methods and coated substrates find particular applicability in the manufacture of semiconductor devices.

Подробнее
10-01-2013 дата публикации

Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same

Номер: US20130011788A1
Принадлежит: International Business Machines Corp

The present invention relates to a fluorine-free photoacid generator (PAG) and a photoresist composition containing the same. The PAG is characterized by the presence of an onium cationic component and a fluorine-free fused ring heteroaromatic sulfonate anionic component containing one or more electron withdrawing substituents. The onium cationic component of the PAG is preferably a sulfonium or an iodonium cation. The photoresist composition further contains an acid sensitive imaging polymer. The photoresist composition is especially useful for forming material patterns on a semiconductor substrate using 193 nm (ArF) lithography.

Подробнее
10-01-2013 дата публикации

Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same

Номер: US20130011793A1
Принадлежит: International Business Machines Corp

The present invention relates to a fluorine-free photoacid generator (PAG) and a photoresist composition containing the same. The PAG is characterized by the presence of an onium cationic component and a fluorine-free fused ring heteroaromatic sulfonate anionic component containing one or more electron withdrawing substituents. The onium cationic component of the PAG is preferably a sulfonium or an iodonium cation. The photoresist composition further contains an acid sensitive imaging polymer. The photoresist composition is especially useful for forming material patterns on a semiconductor substrate using 193 nm (ArF) lithography.

Подробнее
24-01-2013 дата публикации

Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions

Номер: US20130023586A1
Принадлежит: INTERMED DISCOVERY GMBH

A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic—including prophylactic—treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

Подробнее
31-01-2013 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20130028859A1
Принадлежит: Bristol Myers Squibb Co

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Подробнее
21-02-2013 дата публикации

Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes

Номер: US20130045931A1

The invention relates to a compound of the general structure (I), where R is a hydrogen atom (H) or an unsubstituted, monosubstituted, or polysubstituted C 1 -C 20 alkyl, wherein the alkyl can be straight, branched, cyclic, or partially unsaturated, or an unsubstituted, monosubstituted, or polysubstituted phenyl group.

Подробнее
28-02-2013 дата публикации

Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Номер: US20130053351A1
Принадлежит: Bionomics Ltd

The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.

Подробнее
28-02-2013 дата публикации

Gas separations with redox-active metal-organic frameworks

Номер: US20130053585A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Fe 2 (dobdc) has a metal-organic framework with a high density of coordinatively-unsaturated Fe II centers lining the pore surface. It can be effectively used to separate O 2 from N 2 and in a number of additional separation applications based on selective, reversible electron transfer reactions. In addition to being an effective O 2 separation material, it can be used for many other processes, including paraffin/olefin separation, nitric oxide/nitrous oxide separation, acetylene storage, and as an oxidation catalyst.

Подробнее
21-03-2013 дата публикации

Process for Producing Aliskiren

Номер: US20130071899A1
Принадлежит: Chemo Iberica SA

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described.

Подробнее
21-03-2013 дата публикации

COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS

Номер: US20130072473A1
Принадлежит:

The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis. 112-. (canceled)1427-. (canceled)28. The method of claim 13 , wherein Dis N(R) and wherein each Ris independently selected from the group consisting of hydrogen and optionally substituted C-Calkyl.2932-. (canceled)33. The method of claim 28 , wherein Gis an optionally substituted 5/6-membered fused heteroaryl.34. The method of claim 33 , wherein Gis benzothiazolyl claim 33 , benzoxazolyl claim 33 , benzimidazolyl claim 33 , benzothiophenyl claim 33 , and benzofuranyl claim 33 , each optionally substituted.3646-. (canceled)47. The method of claim 35 , wherein Gis an optionally substituted 5/6-membered fused heteroaryl.48. The method of claim 47 , wherein Gis benzothiazolyl claim 47 , benzoxazolyl claim 47 , benzimidazolyl claim 47 , benzothiophenyl claim 47 , and benzofuranyl claim 47 , each optionally substituted.5065-. (canceled)70. The method of claim 13 , wherein the condition is associated with a dysfunction in the proteostasis of a protein selected from the group consisting of hexosamine A claim 13 , cystic fibrosis transmembrane conductance regulator claim 13 , aspartylglucsaminidase claim 13 , a-galactosidase A claim 13 , cysteine transporter claim 13 , acid ceremidase claim 13 , acid α-L-fucosidase claim 13 , protective protein claim 13 , cathepsin A claim 13 , acid β-glucosidase claim 13 , acid β-galactosidase claim 13 , iduronate 2-sulfatase claim 13 , α-L-iduronidase claim 13 , galactocerebrosidase claim 13 , acid α-mannosidase claim 13 , acid β-mannosidase claim 13 , arylsulfatase B claim 13 , arylsulfatase A claim 13 , N-acetylgalactosamine-6-sulfate sulfatase claim 13 , acid β-galactosidase claim 13 , N-acetylglucosamine-1-phosphotransferase claim 13 , acid sphingmyelinase ...

Подробнее
21-03-2013 дата публикации

2-PHENYL BENZOYLAMIDES

Номер: US20130072519A1
Принадлежит:

Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein. 2. A compound according to wherein Ris —C(O)—N—RRand q is 0.5. A compound according to wherein p is 0 and Ris hydrogen or (C-C)alkyl.6. A compound according to wherein Ris —C(O)—O—(C-C)alkyl.7. A compound according to wherein m and n are each independently 0 or 1 and Rand Rare each independently (C-C)alkyl claim 6 , (C-C)alkoxy or trifluoromethyl.8. The compound:Ethyl (1R)-1-({2-[3-(Dimethylcarbamoyl)-4-({[6-methyl-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-{[(4′-isopropoxybiphenyl-2-yl)carbonyl]amino}phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl 1-({2-[3-(dimethylcarbamoyl)-4-({[5-methyl-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl 7-({2-[3-(dimethylcarbamoyl)-4-({[5-methyl-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-7-carboxylate;Ethyl 7-({2-[3-(dimethylcarbamoyl)-4-({[6-methyl-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-7-carboxylate:Ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-({[5-methoxy-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-({[6-methoxy-4′-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-{[(4′-isopropoxy-5-methylbiphenyl-2-yl)carbonyl]amino}phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate;Ethyl 7-({2-[3-(dimethylcarbamoyl)-4-{[(4′-isopropoxybiphenyl-2-yl)carbonyl]amino}phenyl]acetoxy}methyl ...

Подробнее
21-03-2013 дата публикации

CRYSTALLINE HYDROCHLORIDE SALT OF DARUNAVIR

Номер: US20130072552A1
Принадлежит: HETERO RESEARCH FOUNDATION

The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. 1. A crystalline hydrochloride salt of darunavir.2. The crystalline hydrochloride salt of darunavir according to claim 1 , which is characterized by peaks in the powder x-ray diffraction spectrum having 2θ angle positions at about 6.7 claim 1 , 8.0 claim 1 , 13.1 claim 1 , 13.9 claim 1 , 14.9 claim 1 , 19.6 claim 1 , 19.9 claim 1 , 24.5 and 27.9±0.2 degrees.3. The crystalline hydrochloride salt of darunavir according to claim 1 , which is characterized by an x-ray powder diffractogram as shown in .4. A process for the preparation of crystalline hydrochloride salt of darunavir as defined in claim 1 , which comprises:a. providing a solution of darunavir in a solvent;b. adding hydrochloric acid to the solution obtained in step (a);c. slurrying the reaction mass obtained in step (b) at below 40° C.; andd. isolating crystalline hydrochloride salt of darunavir.5. The process according to claim 4 , wherein the solvent used in step (a) is a solvent or mixture of solvents selected from the group consisting of water; a halogenated hydrocarbon solvents are dichloromethane claim 4 , chloroform claim 4 , carbontetrachloride and ethylene dichloride; an ester solvents are ethyl acetate claim 4 , methyl acetate claim 4 , isopropyl acetate claim 4 , tert-butyl methyl acetate and ethyl formate; a ketonic solvents are acetone claim 4 , methyl ethyl ketone claim 4 , methyl isobutyl ketone and diethyl ketone; an ether solvents are tetrahydrofuran claim 4 , 1 claim 4 ,4-dioxane claim 4 , methyl tert-butyl ether claim 4 , diisopropyl ether and diethyl ether.6. The process according to claim 5 , wherein the solvent is water claim 5 , dichloromethane claim 5 , ethyl acetate claim 5 , methyl ...

Подробнее
21-03-2013 дата публикации

PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN

Номер: US20130072695A1
Принадлежит: Alphora Research Inc.

Fused cyclopentane—4-substituted 3,5-dioxalane lactone compounds useful as an intermediate in the synthesis of prostaglandin analogs are provided. The compounds have the formula A: 2. Compound A according to wherein R represents a substituted phenyl group.3. Compound A according to wherein R represents p-methoxyphenyl5. Compound B according to wherein R′ represents p-methoxybenzyl. This invention relates to prostaglandin analogs and their synthesis. More particularly, it relates to a novel, simplified synthesis of prostaglandin analogs, and novel chemical compounds useful as intermediates in such synthesis.Prostaglandins (PGs) are organic carboxylic acids, namely cyclopentanes carrying two side chain substituents, typically linear C6-C8 side chains, bonded to adjacent positions on the cyclopentane nucleus. One of the side chains, the α-side chain, carries a terminal carboxylic acid group. Many are natural products found in mammalian organs and tissues (primary PGs), and exhibit a variety of physiological activities. Primary PGs generally have a prostanoic acid skeleton, which forms the basis of the nomenclature:A significant number of synthetic PG analogs have been made and found to have useful pharmacological properties. These may have modified skeletons, and substituted and unsaturated side chains. PGs are characterized by a hydroxyl (or ketone) substituent on the cyclopentane nucleus, position 9.Prostaglandin analogs are difficult to synthesize. Complications arise because of the requirements of the end products to have several functional groups and two side chains of significant size and complexity. Stereospecificity is commonly required, for substituent groups and for bonds in the core. Since the products are intended for pharmaceutical use, the range of industrially acceptable reagents, solvents, catalysts, etc. which can be used in their synthesis is limited to those having pharmaceutical industry acceptability.A common starting material for PG analog ...

Подробнее
21-03-2013 дата публикации

PREPARATION PROCESS OF DRONEDARONE AND ITS SALTS

Номер: US20130072697A1
Принадлежит: JIANGSU HENGRUI MEDICINE CO., LTD.

A process is provided for preparing dronedarone or pharmaceutically acceptable salts thereof. The process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) with methanesulfonyl chloride without any catalyst to provide crude dronedarone hydrochloride, which is purified to afford highly pure product. Then, the dronedarone hydrochloride can be converted to highly pure dronedarone through treatment with an alkaline solvent, the dronedarone can be further converted to other pharmaceutically acceptable salts of dronedarone. In this process, acylation between compound A and methanesulfonyl chloride is carried out successfully and the formation of the dimethylsulfonyl by-product is inhibited. 1. A process for preparing dronedarone hydrochloride , wherein the process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran with methanesulfonyl chloride to provide dronedarone hydrochloride , wherein no catalyst is added to the reaction.2. The process according to claim 1 , wherein the reaction between 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran and methanesulfonyl chloride is carried out in one solvent or a mixture of multiple solvents.3. The process according to claim 2 , wherein the solvents are selected from the group consisting of a nitrile claim 2 , ketone claim 2 , halogenated hydrocarbon claim 2 , ether and aromatic hydrocarbon.4. The process according to claim 2 , wherein the mixture comprises two or more solvents of the same or different kinds selected from the group consisting of a nitrile claim 2 , ketone claim 2 , halogenated hydrocarbon claim 2 , ether and aromatic hydrocarbon.5. The process according to claim 3 , wherein the nitrile is selected from the group consisting of C2˜C6 aliphatic nitriles.6. The process according to claim 3 , wherein the ketone is selected from the group consisting of C3˜C6 aliphatic ketones.7. The process according to claim 3 , wherein the ...

Подробнее
21-03-2013 дата публикации

PROCESS AND APPARATUS FOR THE PRODUCTION OF ETHYLENE OXIDE

Номер: US20130072700A1
Принадлежит: SHELL OIL COMPANY

The invention provides a process and an apparatus for the production of ethylene oxide from ethylene. Ethylene and oxygen are supplied to reactor tubes, wherein the reactor tubes are held by upper and lower tube sheets in a reactor vessel. The reactor vessel has a separation grid, dividing the reactor vessel into an upstream zone and a downstream zone. Coolant is supplied to the upstream zone from an upper coolant circuit and is removed from the upstream zone to the upper coolant circuit. A portion of coolant is removed as vapour from the upper coolant circuit. Coolant is supplied to the downstream zone from a lower coolant circuit and is removed from the downstream zone to the lower coolant circuit. Additional coolant is added to the lower coolant circuit. There is net flow of coolant through the separation grid from the downstream zone to the upstream zone. 1. A process for the production of ethylene oxide from ethylene comprising:a) supplying ethylene and oxygen to a reactor vessel comprising reactor tubes and a separation grid, wherein the reactor tubes are held by upper and lower tube sheets, and wherein the separation grid divides the reactor vessel into an upstream zone and a downstream zone;b) supplying coolant to the upstream zone from an upper coolant circuit, removing coolant from the upstream zone to the upper coolant circuit, and removing a portion of coolant as vapour from the upper coolant circuit; andc) supplying coolant to the downstream zone from a lower coolant circuit, removing coolant from the downstream zone to the lower coolant circuit and adding additional coolant to the lower coolant circuit;wherein there is net flow of coolant through the separation grid from the downstream zone to the upstream zone.2. A process according to wherein the separation grid has an open area that represents from 0.5 to 8% of the cross section of the reactor vessel.3. A process according to wherein the upstream zone represents from 50 to 95% of the reactor vessel ...

Подробнее
28-03-2013 дата публикации

NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS

Номер: US20130079293A1

Isolated compounds from refined fractions and compositions containing the compounds are provided by the present invention. refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention. 10. The compound of claim 9 , wherein Ris H.11. The compound of claim 9 , wherein{'sup': '1', 'Ris H;'}{'sup': 2', '3, 'each of Rand Rare Me; and'}subscript n is 10.1514. A pharmaceutical composition for treating a neurodegenerative disease or neuropathological condition in a subject claims 1 , the composition comprising a compound of any one of - and a pharmaceutically acceptable carrier or excipient.16Adelostemma gracillimum. A method of preparing a refined fraction claims 1 , the method comprising:{'i': 'Adelostemma gracillimum', 'contacting herb with an alcohol selected from the group consisting of methanol and ethanol, to form an alcohol extract;'}contacting the alcohol extract with an organic solvent to form an organic solvent fraction; and{'i': 'Adelostemma gracillimum', 'contacting the organic solvent fraction with a petroleum ether to form the refined fraction.'}17. The method of claim 16 , further comprising:{'i': 'Adelostemma gracillimum', 'eluting a first fraction of the refined fraction from a resin column with a solution of about 30% ethanol in water;'}eluting a second fraction from the resin column with a solution of about 60% ethanol in water; andeluting a third fraction from the resin column with a solution of about 96% ethanol in water.18Adelostemma gracillimum. An refined fraction prepared by the method of .19Adelostemma gracillimum. An refined fraction prepared by the method of .20Adelostemma gracillimum. A method of improving memory in a subject claim 17 , ...

Подробнее
28-03-2013 дата публикации

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

Номер: US20130079306A1
Принадлежит: Individual

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

Подробнее
28-03-2013 дата публикации

PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES

Номер: US20130079397A1
Принадлежит: Takeda Pharmaceutical Company Limited

An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. 15-. (canceled)61. A process for producing crystals of (S)—N-[2-(1 ,6 ,7 ,8-tetrahydro-2H-indeno[5 ,4-b]furan-8-yl)ethyl]propionamide , comprising step (a): a step for propionylating the amino group of (S)—N-[2-(1 ,6 ,7 ,8-tetrahydro-2H-indeno[5 ,4-b]furan-8-yl)ethylamine or a salt thereof obtained in the process according to claim , and step (b): a step for crystallizing by adding aqueous solvent to the reaction solution obtained in step (a).9. The crystals according to or , wherein the content of the compound represented by formula (I) is 0.10% by weight or less.13. The crystals according to or the composition according to , which is prepared on a commercial scale.14. A process for producing 1 ,2 ,6 ,7-tetrahydro-8H-indeno[5 ,4-b]furan-8-one , comprising a step for reducing 4 ,5-dibromo-1 ,2 ,6 ,7-tetrahydro-8H-indeno[5 ,4-b]furan-8-one with Pd—C catalyst under the condition:hydrogen pressure (MPa)>−0.02×gas-liquid overall mass transfer volume coefficient (1/hr)+0.43.15. Use of the crystals according to for the manufacture of a preventive or therapeutic agent for sleep disorder.16. The composition according to which is a preventive or therapeutic agent for sleep disorder.17. A method for the prevention or treatment of sleep disorder claim 10 , comprising administering the crystals according to or the composition according to . The present invention relates to a process for production of an optically active amine derivative having high purity, ...

Подробнее